首页> 外文期刊>Asian Journal of Pharmaceutical Sciences >In?vitro and in?vivo evaluation of gastroretentive floating drug delivery system of ofloxacin
【24h】

In?vitro and in?vivo evaluation of gastroretentive floating drug delivery system of ofloxacin

机译:氧氟沙星胃滞留漂浮药物递送系统的体外和体内评价

获取原文

摘要

Abstract This study aimed to develop hydrophilic matrix based controlled release gastroretentive drug delivery system of ofloxacin and conducting its in?vitro and in?vivo evaluations. Effervescent floating gastroretentive drug delivery system of ofloxacin was prepared utilizing Box–Behnken statistical design with 3 factors, 3 levels and 15 experimental trials. Formulation optimization was done by setting targets on selected responses. In?vivo studies were carried out for the optimized formulation with 12 healthy human volunteers and obtained pharmacokinetic parameters were compared with the marketed once daily formulation, “Zanocin OD”. Optimized formulation showed satisfactory controlled in?vitro drug release for more than 12?h with excellent buoyancy properties (floating lag time 1?min, floating duration 16?h). Optimized and marketed formulations were found to have similar in?vitro release profile (f2?=?79.22) and also were found to be bioequivalent. Serum ofloxacin concentration was well maintained above its reported minimum inhibitory concentrations for most of the pathogens for sufficiently longer duration. Cmax and {AUC} values of optimized formulation were found to be significantly higher than of marketed product despite their bioequivalence. Bettertherapeutic effect can be expected since ofloxacin exhibits concentration dependent killing. Hence, gastroretention can be a promising approach to enhance bioavailability of ofloxacin with narrow absorption window in upper GIT.
机译:摘要本研究旨在开发基于氧氟沙星的亲水性基质控释胃滞留给药系统,并进行体内和体外评价。氧氟沙星泡腾漂浮性胃滞留药物递送系统是采用Box-Behnken统计设计方法制备的,其中包括3个因素,3个水平和15个试验。通过在所选响应中设置目标来完成配方优化。进行了针对12位健康人类志愿者的优化制剂的体内研究,并将获得的药代动力学参数与市售的每日一次制剂“ Zanocin OD”进行了比较。优化的配方显示出令人满意的体外药物释放控制超过12 h,具有出色的浮力特性(漂浮滞后时间<1μmin,漂浮持续时间> 16 h)。发现优化的和市售的制剂具有相似的体外释放曲线(f 2 == 79.22),并且也发现具有生物等效性。对于大多数病原体,氧氟沙星的血清浓度可以保持足够长的时间,高于其报告的最低抑菌浓度。尽管具有生物等效性,但优化配方的Cmax和 {AUC }值仍显着高于市售产品。氧氟沙星表现出浓度依赖性杀伤作用,因此有望获得更好的治疗效果。因此,胃滞留可能是一种在上部GIT吸收窗较窄的情况下提高氧氟沙星生物利用度的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号